SUPPLEMENTAL MATERIAL

	Resistant hypertension (+)			Resistant hypertension (-)		
	Placebo Spironolactone P value		Placebo	Spironolactone	P value	
	n = 457	n = 451		n = 1,263	n = 1,270	
Event						
Primary outcome events [†]						
No. of patients	117	82		231	238	
Event rate (per 1,000 person-year)	88.9	57.5		59.3	59.1	
HR (95% CI)	1.00 (ref)	0.66 (0.50-0.88)	0.004	1.00 (ref)	1.01 (0.84–1.21)	0.90
All-cause death						
No. of patients	73	42		200	214	
Event rate (per 1,000 person-year)	48.5	27.1		46.9	50.2	
HR (95% CI)	1.00 (ref)	0.56 (0.38-0.82)	0.002	1.00 (ref)	1.07 (0.88–1.30)	0.47
Cardiovascular death						
No. of patients	44	24		132	136	
Event rate (per 1,000 person-year)	29.2	15.5		30.9	31.9	
HR (95% CI)	1.00 (ref)	0.53 (0.32-0.87)	0.01	1.00 (ref)	1.03 (0.81–1.31)	0.78
Non-cardiovascular death						
No. of patients	29	18		68	78	
Event rate (per 1,000 person-year)	19.3	11.6		15.9	18.3	
HR (95% CI)	1.00 (ref)	0.60 (0.33–1.09)	0.09	1.00 (ref)	1.15 (0.83–1.59)	0.40
Hospitalization for heart failure						
No. of patients	94	70		151	136	
Event rate (per 1,000 person-year)	71.2	49.1		37.6	33.8	
HR (95% CI)	1.00 (ref)	0.71 (0.52-0.96)	0.02	1.00 (ref)	0.89 (0.71–1.13)	0.34
Major cardiovascular events [‡]						
No. of patients	68	48		196	193	
Event rate (per 1,000 person-year)	46.9	31.8		47.3	46.3	
HR (95% CI)	1.00 (ref)	0.68 (0.47-0.99)	0.04	1.00 (ref)	0.98 (0.80–1.19)	0.83
Myocardial infarction						
No. of patients	18	18		46	47	
Event rate (per 1,000 person-year)	12.3	11.8		11.0	11.3	

Table S1. Primary and secondary outcomes in HFpEF patients with or without traditional resistant hypertension*.

HR (95% CI)	1.00 (ref)	0.98 (0.51–1.88)	0.94	1.00 (ref)	1.02 (0.68–1.53)	0.92
Stroke						
No. of patients	13	16		47	41	
Event rate (per 1,000 person-year)	8.8	10.5		11.2	9.8	
HR (95% CI)	1.00 (ref)	1.22 (0.59–2.54)	0.59	1.00 (ref)	0.87 (0.57–1.32)	0.50

*Data are presented as number or hazard ratio (95% confidence interval). Bold font denotes significance.

[†]The primary outcome was a composite of cardiovascular death, aborted cardiac arrest, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for the management of heart failure.

[‡]Major cardiovascular events included cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke.

HFpEF, heart failure with preserved left ventricular ejection fraction; HR, hazard ratio; CI, confidence interval.

Table S2. Primary and secondary outcomes in HFpEF patients with uncontrolled blood pressure despite the concurrent use of an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, a calcium channel blocker, and a diuretic*.

	Placebo n = 353	Spironolactone n = 343	P value	
Event				
Primary outcome events [†]				
No. of patients	70	49		
Event rate (per 1,000 person-year)	63.9	43.1		
HR (95% CI)	1.00 (ref)	0.68 (0.47-0.98)	0.04	
All-cause death				
No. of patients	38	27		
Event rate (per 1,000 person-year)	31.3	22.6		
HR (95% CI)	1.00 (ref)	0.72 (0.44–1.18)	0.19	
Cardiovascular death	. ,			
No. of patients	26	17		
Event rate (per 1,000 person-year)	21.4	14.2		
HR (95% CI)	1.00 (ref)	0.66 (0.36–1.22)	0.18	
Non-cardiovascular death				
No. of patients	12	10		
Event rate (per 1,000 person-year)	9.9	8.4		
HR (95% CI)	1.00 (ref)	0.84 (0.36–1.96)	0.69	
Hospitalization for heart failure				
No. of patients	57	36		
Event rate (per 1,000 person-year)	52.0	31.6		
HR (95% CI)	1.00 (ref)	0.62 (0.41-0.94)	0.02	
Major cardiovascular events [‡]				
No. of patients	38	35		
Event rate (per 1,000 person-year)	31.9	30.2		
HR (95% CI)	1.00 (ref)	0.95 (0.60–1.50)	0.81	
Myocardial infarction				
No. of patients	8	13		

Event rate (per 1,000 person-year) HR (95% CI)	6.7 1.00 (ref)	11.1 1.68 (0.69–4.05)	0.25
Stroke			
No. of patients	9	10	
Event rate (per 1,000 person-year)	7.5	8.5	
HR (95% CI)	1.00 (ref)	1.14 (0.46–2.80)	0.78

*Data are presented as number or hazard ratio (95% confidence interval). Uncontrolled blood pressure was defined as systolic blood pressure \geq 130 mm Hg and/or diastolic blood pressure \geq 80 mm Hg. Bold font denotes significance.

[†]The primary outcome was a composite of cardiovascular death, aborted cardiac arrest, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for the management of heart failure.

[‡]Major cardiovascular events included cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke.

HFpEF, heart failure with preserved left ventricular ejection fraction; HR, hazard ratio; CI, confidence interval.

Table S3. Primary and secondary outcomes in HFpEF patients from the Americas with or without resistant hypertension*.

	Resistant hypertension (+)		Resistant hypertension (-)			
	Placebo	Spironolactone	P value	Placebo	Spironolactone	P value
	n = 284	n = 270		n = 595	n = 615	
Event						
Primary outcome events [†]						
No. of patients	105	73		175	169	
Event rate (per 1,000 person-year)	156.0	102.4		112.6	103.0	
HR (95% CI)	1.00 (ref)	0.66 (0.48–0.89)	0.006	1.00 (ref)	0.92 (0.74–1.13)	0.50
All-cause death						
No. of patients	66	35		139	146	
Event rate (per 1,000 person-year)	78.7	42.5		78.9	79.4	
HR (95% CI)	1.00 (ref)	0.53 (0.35-0.80)	0.002	1.00 (ref)	1.00 (0.79–1.26)	0.96
Cardiovascular death						
No. of patients	37	18		90	78	
Event rate (per 1,000 person-year)	44.1	21.9		51.1	42.4	
HR (95% CI)	1.00 (ref)	0.49 (0.27-0.86)	0.01	1.00 (ref)	0.83 (0.61–1.12)	0.23
Non-cardiovascular death						
No. of patients	29	17		49	68	
Event rate (per 1,000 person-year)	34.6	20.7		27.8	36.9	
HR (95% CI)	1.00 (ref)	0.58 (0.32–1.07)	0.08	1.00 (ref)	1.32 (0.91–1.90)	0.13
Hospitalization for heart failure						
No. of patients	87	65		129	134	
Event rate (per 1,000 person-year)	128.4	91.2		82.7	72.5	
HR (95% CI)	1.00 (ref)	0.72 (0.51-0.98)	0.04	1.00 (ref)	0.88 (0.68–1.13)	0.30
Major cardiovascular events [‡]						
No. of patients	57	37		132	115	
Event rate (per 1,000 person-year)	72.0	46.5		78.8	64.5	
HR (95% CI)	1.00 (ref)	0.65 (0.42-0.97)	0.03	1.00 (ref)	0.82 (0.64–1.05)	0.11
Myocardial infarction						
No. of patients	17	14		29	34	

Event rate (per 1,000 person-year) HR (95% CI)	21.3 1.00 (ref)	17.5 0.83 (0.40–1.67)	0.59	17.0 1.00 (ref)	19.2 1.11 (0.68–1.84)	0.65
Stroke	1.00 (101)	0.00 (0.10 1107)	0.09			0102
No. of patients	10	13		29	25	
Event rate (per 1,000 person-year)	12.2	16.1		17.0	13.8	
HR (95% CI)	1.00 (ref)	1.33 (0.58–3.03)	0.49	1.00 (ref)	0.81 (0.47-1.38)	0.43

*Data are presented as number or hazard ratio (95% confidence interval). Bold font denotes significance.

[†]The primary outcome was a composite of cardiovascular death, aborted cardiac arrest, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for the management of heart failure.

[‡]Major cardiovascular events included cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke.

HFpEF, heart failure with preserved left ventricular ejection fraction; HR, hazard ratio; CI, confidence interval.

	Res	Resistant hypertension (+)			Resistant hypertension (–)		
	Placebo n = 499	Spironolactone n = 505	P value	Placebo n = 1,221	Spironolactone n = 1,216	P value	
Serum potassium ≥5.5 mmol/L on lowest							
spironolactone dose (15 mg)							
No. of patients	4	40		16	62		
Event rate (per 1,000 person-year)	3.0	30.0		4.7	19.6		
HR (95% CI)	1.00 (ref)	9.97 (3.57–27.88)	< 0.001	1.00 (ref)	4.00 (2.31–6.94)	< 0.001	
Serious hyperkalemia							
No. of patients	2	17		15	29		
Event rate (per 1,000 person-year)	1.5	12.7		4.4	9.2		
HR (95% CI)	1.00 (ref)	8.66 (2.00–37.50)	0.003	1.00 (ref)	2.02 (1.08-3.77)	0.02	
Breast tenderness or enlargement							
No. of patients	1	9		4	34		
Event rate (per 1,000 person-year)	0.7	6.7		1.2	10.7		
HR (95% CI)	1.00 (ref)	9.15 (1.16–72.23)	0.03	1.00 (ref)	8.86 (3.14–24.97)	0.34	
Anaphylactoid reaction or intolerance [†]							
No. of patients	2	1		8	5		
Event rate (per 1,000 person-year)	1.5	0.7		2.4	1.6		
HR (95% CI)	1.00 (ref)	0.49 (0.04–5.46)	0.56	1.00 (ref)	0.63 (0.21–1.94)	0.42	

Table S4. Spironolactone use and study discontinuation in HFpEF patients with or without resistant hypertension*.

*Data are presented as number or hazard ratio (95% confidence interval). Serious hyperkalemia was defined as potassium ≥6.0 mmol/L based on a nonhemolyzed sample. [†]None were anaphylactoid reaction.





Figure S1. Mean systolic and diastolic blood pressure levels during follow-up in HFpEF patients with and without resistant hypertension.

Mean systolic and diastolic blood pressure levels during follow-up in HFpEF patients, with (A and C) and without (B and D) resistant hypertension. HFpEF, heart failure with preserved ejection fraction.

Figure S2. Kaplan–Meier survival curves for primary outcome in HFpEF patients with or without traditional resistant hypertension.




A. Primary outcome events in patients with resistant hypertension

1.00 -Event-free survival rate Spironolactone Placebo P = 0.900.50 2 Years 4 6 0 No. at risk 455 1,270 878 36 Spironolactone Placebo 1,263 460 41 872


Rates of freedom from primary outcome events in HFpEF patients, with (A) and without (B) traditional resistant hypertension. The primary outcome was a composite of cardiovascular death, aborted cardiac arrest, or hospitalization for heart failure. HFpEF, heart failure with preserved ejection fraction.

Supplemental Figure 3. Kaplan–Meier survival curves for all-cause death and heart failure hospitalization in HFpEF patients with or without traditional resistant hypertension.




Rates of freedom from all-cause death (A and C) and hospitalization for heart failure (B and D). HFpEF, heart failure with preserved ejection fraction; HF, heart failure.

Figure S4. Kaplan–Meier survival curves for primary outcome in HFpEF patients from the Americas with or without resistant hypertension.




A. Primary outcome in patients from the Americas with resistant hypertension





Rates of freedom from primary outcome events in HFpEF patients from Americas, with (A) and without (B) resistant hypertension. The primary outcome was a composite of cardiovascular death, aborted cardiac arrest, or hospitalization for heart failure. HFpEF, heart failure with preserved ejection fraction.

Figure S5. Kaplan–Meier survival curves for all-cause death and heart failure hospitalization in HFpEF patients from the Americas with or without resistant hypertension.



Rates of freedom from all-cause death (A and C) and hospitalization for heart failure (B and D). HFpEF, heart failure with preserved ejection fraction; HF, heart failure.